Roberto José Carvalho Filho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Roberto José Carvalho Filho has a total of 197 co-authors. Here are the top co-authors by number of shared publications:
- Janaína Luz Narciso-Schiavon
Department of Internal Medicine, Gastroenterology Division, Federal University of Santa Catarina, Florianópolis 88040-900, Santa Catarina, Brazil.
18 shared publications - Leonardo de Lucca Schiavon
Universidade Federal de Santa Catarina
16 shared publications - Maria Lucia Gomes Ferraz
Universidade Federal de São Paulo
9 shared publications Antonio Eduardo B. Silva
Federal University of São Paulo
8 shared publicationsMaria Lucia G. Ferraz
Federal University of São Paulo
8 shared publicationsValéria P. Lanzoni
Federal University of São Paulo
7 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista Brasileira de Educação Médica
- Vol. 50 (3)
Training in Transient Liver Elastography (FibroScan®) During Medical Residency: Examination Quality in a Real-World Study
Introduction: The incorporation of transient elastography (TE) has been recognized as a useful tool for identifying patients at risk for advanced liver disease. However, limited attention has been given to the importance of consistent, high-quality training in this method. Objective: To evaluate the quality of TE examinations by FibroScan® and the learning curve of medical residents during residency training. Methods: FibroScan® examinations performed between 2022 and 2025 by residents enrolled in the gastrohepatology residency program were analyzed. Year of examination, etiology, probe type (M and XL), kPa measurements, kPa IQR/median, CAP, CAP IQR, and operator, were assessed. All patients were adults with chronic liver disease of various etiologies and had a medical indication for liver stiffness assessment. Results: A total of 1,662 FibroScan® examinations were analyzed. Overall, 96 examinations (5.8%) were classified as failures. The main indications for examination were MASLD (n=397; 25.4%), AIH (n=201; 12.8%), HCV/HBV (n=337; 21,5%), alcohol (n=124; 7.9%), and PBC/PSC (n=99; 6.3%). The M and XL probes were used in 53.9% and 46.1% of cases, respectively. 98.1% (n=1,537) showed IQR/median values ≤0.30; of these, 27.6% (n=425) were classified as “very reliable” (IQR/median ≤0.10), 72.4% (n=1,112) as “reliable” (IQR/median >0.10 to ≤0.30), and 1.85% (n=29) as “unreliable” (>0.30). No significant differences were identified regarding examination failure rate, kPa values, IQR/median, or operator, over the years. An increase was observed in the use of the XL probe (29.5% vs 54.8%; p<0.001), in the number of “very reliable” examinations (24% vs 31.5%; p<0.001), and a reduction in “unreliable” examinations (3.8% vs 1.8%; p=0.024) over the study period. When operators were evaluated, no significant differences were found in relation to any of the analyzed parameters. Conclusion: The incorporation of supervised training in TE by FibroScan®, for residents in training, should be encouraged, with a very short learning to achieve reliable examinations.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista Brasileira de Educação Médica
- Vol. 50 (3)
Open AccessTraining in Transient Liver Elastography (FibroScan®) During Medical Residency: Examination Quality in a Real-World Study
Introduction: The incorporation of transient elastography (TE) has been recognized as a useful tool for identifying patients at risk for advanced liver disease. However, limited attention has been given to the importance of consistent, high-quality training in this method. Objective: To evaluate the quality of TE examinations by FibroScan® and the learning curve of medical residents during residency training. Methods: FibroScan® examinations performed between 2022 and 2025 by residents enrolled in the gastrohepatology residency program were analyzed. Year of examination, etiology, probe type (M and XL), kPa measurements, kPa IQR/median, CAP, CAP IQR, and operator, were assessed. All patients were adults with chronic liver disease of various etiologies and had a medical indication for liver stiffness assessment. Results: A total of 1,662 FibroScan® examinations were analyzed. Overall, 96 examinations (5.8%) were classified as failures. The main indications for examination were MASLD (n=397; 25.4%), AIH (n=201; 12.8%), HCV/HBV (n=337; 21,5%), alcohol (n=124; 7.9%), and PBC/PSC (n=99; 6.3%). The M and XL probes were used in 53.9% and 46.1% of cases, respectively. 98.1% (n=1,537) showed IQR/median values ≤0.30; of these, 27.6% (n=425) were classified as “very reliable” (IQR/median ≤0.10), 72.4% (n=1,112) as “reliable” (IQR/median >0.10 to ≤0.30), and 1.85% (n=29) as “unreliable” (>0.30). No significant differences were identified regarding examination failure rate, kPa values, IQR/median, or operator, over the years. An increase was observed in the use of the XL probe (29.5% vs 54.8%; p<0.001), in the number of “very reliable” examinations (24% vs 31.5%; p<0.001), and a reduction in “unreliable” examinations (3.8% vs 1.8%; p=0.024) over the study period. When operators were evaluated, no significant differences were found in relation to any of the analyzed parameters. Conclusion: The incorporation of supervised training in TE by FibroScan®, for residents in training, should be encouraged, with a very short learning to achieve reliable examinations.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista Brasileira de Educação Médica
- Vol. 50 (3)
Treinamento em elastografia hepática transitória (FibroScan®) durante a residência médica: estudo de vida real.
RESUMO Introdução: A incorporação da elastografia hepática transitória (EHT) tem sido apontada como uma ferramenta útil para identificar pacientes de maior risco para doença hepática avançada. Porém, pouco se discute sobre a importância de um aprendizado consistente e de qualidade sobre o método. Objetivo: Avaliar a qualidade das EHT por meio do Fibroscan® e a curva de aprendizado dos médicos residentes durante o estágio de residência médica. Métodos: Foram analisados os exames de EHT (Fibroscan®), entre 2022 e 2025, realizados por médicos residentes do programa de residência médica em gastrohepatologia. Ano do exame, etiologia, sonda, medidas de Kpa, IQR/Mediana do Kpa, CAP, IQR do CAP e operador, foram avaliados. Todos os pacientes eram adultos com doença hepática crônica, com indicação médica para avaliação da rigidez hepática. Resultados: Foram analisados 1.662 exames de EHT por Fibroscan®. O total de 96 exames (5,8%) foi considerado “falha”. As etiologias de indicação do exame foram: MASLD (n=397;25,4%); HAI (n=201;12,8%); HCV/HBV (n=337; 21,5%); álcool (n=124; 7,9%); CBP/CEP (n=99; 6,3%). Foram utilizadas as sondas M e XL em 53,9% e 46,1%, respectivamente; 98,1% (N=1537) dos exames apresentaram valores IQR/Ma≤0,30, desses 27,6% (n=425) foram considerados “muito confiáveis” (IQR/Ma≤0,10); 72,4% (n=1112) “confiáveis” (IQR/Ma >0,10-≤0,30) e 1,85% (n=29) “não confiáveis” (>0,30). Não identificamos diferença significativa quanto às falhas das medidas, valores de Kpa, IQR/mediana e quanto ao operador, ao longo dos anos. Observou-se um aumento na utilização da sonda XL (29,5% vs 54,8%; p<0,001), no número de exames “muito confiáveis” (24% vs 31,5%; p<0,001) e uma redução dos exames “não confiáveis” (3,8% vs 1,8%; p=0,024) ao longo dos anos analisados. Ao avaliar os operadores, não encontramos diferença significativa em relação a nenhum dos parâmetros estudados. Conclusão: A incorporação de treinamento supervisionado em EHT (Fibroscan®), para médicos residentes em formação, deve ser estimulada, com uma curva de aprendizado bastante rápida para a realização de exames confiáveis.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista Brasileira de Educação Médica
- Vol. 50 (3)
Open AccessTreinamento em elastografia hepática transitória (FibroScan®) durante a residência médica: estudo de vida real.
RESUMO Introdução: A incorporação da elastografia hepática transitória (EHT) tem sido apontada como uma ferramenta útil para identificar pacientes de maior risco para doença hepática avançada. Porém, pouco se discute sobre a importância de um aprendizado consistente e de qualidade sobre o método. Objetivo: Avaliar a qualidade das EHT por meio do Fibroscan® e a curva de aprendizado dos médicos residentes durante o estágio de residência médica. Métodos: Foram analisados os exames de EHT (Fibroscan®), entre 2022 e 2025, realizados por médicos residentes do programa de residência médica em gastrohepatologia. Ano do exame, etiologia, sonda, medidas de Kpa, IQR/Mediana do Kpa, CAP, IQR do CAP e operador, foram avaliados. Todos os pacientes eram adultos com doença hepática crônica, com indicação médica para avaliação da rigidez hepática. Resultados: Foram analisados 1.662 exames de EHT por Fibroscan®. O total de 96 exames (5,8%) foi considerado “falha”. As etiologias de indicação do exame foram: MASLD (n=397;25,4%); HAI (n=201;12,8%); HCV/HBV (n=337; 21,5%); álcool (n=124; 7,9%); CBP/CEP (n=99; 6,3%). Foram utilizadas as sondas M e XL em 53,9% e 46,1%, respectivamente; 98,1% (N=1537) dos exames apresentaram valores IQR/Ma≤0,30, desses 27,6% (n=425) foram considerados “muito confiáveis” (IQR/Ma≤0,10); 72,4% (n=1112) “confiáveis” (IQR/Ma >0,10-≤0,30) e 1,85% (n=29) “não confiáveis” (>0,30). Não identificamos diferença significativa quanto às falhas das medidas, valores de Kpa, IQR/mediana e quanto ao operador, ao longo dos anos. Observou-se um aumento na utilização da sonda XL (29,5% vs 54,8%; p<0,001), no número de exames “muito confiáveis” (24% vs 31,5%; p<0,001) e uma redução dos exames “não confiáveis” (3,8% vs 1,8%; p=0,024) ao longo dos anos analisados. Ao avaliar os operadores, não encontramos diferença significativa em relação a nenhum dos parâmetros estudados. Conclusão: A incorporação de treinamento supervisionado em EHT (Fibroscan®), para médicos residentes em formação, deve ser estimulada, com uma curva de aprendizado bastante rápida para a realização de exames confiáveis.
- 27 February 2025
- Published by Springer Nature in Hepatology International
- Vol. 19 (5) , 1187-1198
Acute kidney injury stage 1a increases mortality of patients with cirrhosis: a prospective multicenter cohort study
Background and aims Acute kidney injury is a severe complication of cirrhosis. However, the impact of mild decreases in renal function is controversial. This study aims to evaluate the prognosis of the different stages of acute kidney injury in cirrhosis. Methods This is a multicenter prospective cohort study of patients hospitalized for acute decompensation of cirrhosis, with serum creatinine values measured at least twice. Primary outcome was mortality (in-hospital, 30 days, 90 days and 12 months). Results Nine hundred twenty-eight patients were included in the study. Acute kidney injury was diagnosed in 505 patients (stages 1a—21.6%, 1b—27.5%, 2—28.1%, 3—22.8%). Mortality rates of patients with acute kidney injury stage 1a were significantly higher than those of individuals without acute kidney injury (in-hospital—19.3% vs 4.7%; 30-day—21.8% vs 6.7%; 90-day—35.2% vs 17.5%; 12-month—54.1% vs 37.1%; p < 0.05 for all comparisons). Mortality rates were even higher for acute kidney injury stages 1b, 2 and 3. Survival analysis demonstrated that patients without acute kidney injury performed significantly better than those with any stage of acute kidney injury (p < 0.01). Acute kidney injury stages 1a, 1b, 2 and 3 were independently associated with survival in the multivariate analysis (p < 0.01). Conclusions Patients hospitalized for acute decompensation of cirrhosis who develop acute kidney injury have significantly higher mortality rates than those who do not develop this complication. This is true even for the mildest stages of acute kidney injury (stage 1a) and remains so at different time-points, supporting recommendations for earlier treatments. Graphical abstract
- 27 February 2025
- Published by Springer Nature in Hepatology International
- Vol. 19 (5) , 1187-1198
Acute kidney injury stage 1a increases mortality of patients with cirrhosis: a prospective multicenter cohort study
Background and aims Acute kidney injury is a severe complication of cirrhosis. However, the impact of mild decreases in renal function is controversial. This study aims to evaluate the prognosis of the different stages of acute kidney injury in cirrhosis. Methods This is a multicenter prospective cohort study of patients hospitalized for acute decompensation of cirrhosis, with serum creatinine values measured at least twice. Primary outcome was mortality (in-hospital, 30 days, 90 days and 12 months). Results Nine hundred twenty-eight patients were included in the study. Acute kidney injury was diagnosed in 505 patients (stages 1a—21.6%, 1b—27.5%, 2—28.1%, 3—22.8%). Mortality rates of patients with acute kidney injury stage 1a were significantly higher than those of individuals without acute kidney injury (in-hospital—19.3% vs 4.7%; 30-day—21.8% vs 6.7%; 90-day—35.2% vs 17.5%; 12-month—54.1% vs 37.1%; p < 0.05 for all comparisons). Mortality rates were even higher for acute kidney injury stages 1b, 2 and 3. Survival analysis demonstrated that patients without acute kidney injury performed significantly better than those with any stage of acute kidney injury (p < 0.01). Acute kidney injury stages 1a, 1b, 2 and 3 were independently associated with survival in the multivariate analysis (p < 0.01). Conclusions Patients hospitalized for acute decompensation of cirrhosis who develop acute kidney injury have significantly higher mortality rates than those who do not develop this complication. This is true even for the mildest stages of acute kidney injury (stage 1a) and remains so at different time-points, supporting recommendations for earlier treatments. Graphical abstract
- Open Access
- 12 July 2023
- Published by S. Karger AG in GE - Portuguese Journal of Gastroenterology
- Vol. 31 (3) , 173-181
Clinical Characteristics of Genuine Acute Autoimmune Hepatitis
Introduction: Autoimmune hepatitis (AIH) has a spectrum of symptoms ranging from asymptomatic disease to acute severe hepatitis, chronic hepatitis, and decompensated cirrhosis. The acute presentation is not rare and could represent genuine acute AIH (GAAIH) or acute exacerbation of chronic autoimmune hepatitis. We aimed to identify the prevalence, clinical features, and prognostic factors associated with GAAIH and compare these cases with acute exacerbation of chronic AIH. Methods: This cross-sectional observational study evaluated patients with acute AIH presentation, defined as total bilirubin >5 times the upper limit of normality (xULN) and/or alanine aminotransferase >10 xULN, and no prior history of liver disease. Histology findings of acute disease defined GAAIH. Bivariate analyses were performed to identify factors associated with the GAAIH, when compared with acute exacerbation of chronic AIH. Results: Seventy-two patients with acute presentation of AIH were included and six (8.3%) of them presented GAAIH. Comparative analysis between patients with GAAIH and patients with acute exacerbation of chronic AIH revealed that prothrombin activity (96% [74–100] vs. 61% [10–100]; p = 0.003) and albumin levels (3.9 ± 0.2 g/dL vs. 3.4 ± 0.5 g/dL; p < 0.001) were higher in patients with GAAIH. The International Autoimmune Hepatitis Group score was higher in patients with acute exacerbation of chronic AIH (18.5 [8–23] vs. 16.5 [15–17]; p = 0.010). Compared to 15.2% of acute exacerbation of chronic AIH, complete therapeutic response to treatment was achieved in 67.7% of cases with GAAIH (p = 0.018). Conclusions: GAAIH was rare (8.3%), and patients with this presentation exhibited more preserved liver function tests, suggesting that most cases presenting with loss of function are acute exacerbation of chronic AIH. Additionally, patients with GAAIH had a better complete therapeutic response, suggesting a more preserved liver function at presentation, and early diagnosis has a positive therapeutic implication.
- 12 July 2023
- Published by S. Karger AG in GE - Portuguese Journal of Gastroenterology
- Vol. 31 (3) , 173-181
Open AccessClinical Characteristics of Genuine Acute Autoimmune Hepatitis
Introduction: Autoimmune hepatitis (AIH) has a spectrum of symptoms ranging from asymptomatic disease to acute severe hepatitis, chronic hepatitis, and decompensated cirrhosis. The acute presentation is not rare and could represent genuine acute AIH (GAAIH) or acute exacerbation of chronic autoimmune hepatitis. We aimed to identify the prevalence, clinical features, and prognostic factors associated with GAAIH and compare these cases with acute exacerbation of chronic AIH. Methods: This cross-sectional observational study evaluated patients with acute AIH presentation, defined as total bilirubin >5 times the upper limit of normality (xULN) and/or alanine aminotransferase >10 xULN, and no prior history of liver disease. Histology findings of acute disease defined GAAIH. Bivariate analyses were performed to identify factors associated with the GAAIH, when compared with acute exacerbation of chronic AIH. Results: Seventy-two patients with acute presentation of AIH were included and six (8.3%) of them presented GAAIH. Comparative analysis between patients with GAAIH and patients with acute exacerbation of chronic AIH revealed that prothrombin activity (96% [74–100] vs. 61% [10–100]; p = 0.003) and albumin levels (3.9 ± 0.2 g/dL vs. 3.4 ± 0.5 g/dL; p < 0.001) were higher in patients with GAAIH. The International Autoimmune Hepatitis Group score was higher in patients with acute exacerbation of chronic AIH (18.5 [8–23] vs. 16.5 [15–17]; p = 0.010). Compared to 15.2% of acute exacerbation of chronic AIH, complete therapeutic response to treatment was achieved in 67.7% of cases with GAAIH (p = 0.018). Conclusions: GAAIH was rare (8.3%), and patients with this presentation exhibited more preserved liver function tests, suggesting that most cases presenting with loss of function are acute exacerbation of chronic AIH. Additionally, patients with GAAIH had a better complete therapeutic response, suggesting a more preserved liver function at presentation, and early diagnosis has a positive therapeutic implication.
- Open Access
- 5 May 2023
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 18 (1) , 1-11
Hepatic fibrosis: a manifestation of the liver disease evolution in patients with Ataxia-telangiectasia
Background: Ataxia-telangiectasia (A-T) is a DNA repair disorder characterized by changes in several organs and systems. Advances in clinical protocols have resulted in increased survival of A-T patients, however disease progression is evident, mainly through metabolic and liver changes. Objective: To identify the frequency of significant hepatic fibrosis in A-T patients and to verify the association with metabolic alterations and degree of ataxia. Methods: This is a cross-sectional study that included 25 A-T patients aged 5 to 31 years. Anthropometric data, liver, inflammatory, lipid metabolism and glucose biomarkers (oral glucose tolerance test with insulin curve—OGTT) were collected. The Cooperative Ataxia Rating Scale was applied to assess the degree of ataxia. The following were calculated: Homeostasis Model Assessment—Insulin Resistance, Homeostasis Model Assessment—Adiponectin (HOMA-AD), Matsuda index, aspartate aminotransferase (AST): platelet ratio index, nonalcoholic fatty liver disease fibrosis score and BARD score. Liver ultrasonography and transient liver elastography by FibroScan® were performed. Results: Significant hepatic fibrosis was observed in 5/25 (20%). Patients in the group with significant hepatic fibrosis were older (p < 0.001), had lower platelet count values (p = 0.027), serum albumin (p = 0.019), HDL-c (p = 0.013) and Matsuda index (p = 0.044); and high values of LDL-c (p = 0.049), AST (p = 0.001), alanine aminotransferase (p = 0.002), gamma-glutamyl transferase (p = 0.001), ferritin (p = 0.001), 120-min glycemia by OGTT (p = 0.049), HOMA-AD (p = 0.016) and degree of ataxia (p = 0.009). Conclusions: A non-invasive diagnosis of significant hepatic fibrosis was observed in 20% of A-T patients associated with changes in liver enzymes, ferritin, increased HOMA-AD, and the severity of ataxia in comparison with patients without hepatic fibrosis.
- 5 May 2023
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 18 (1) , 1-11
Open AccessHepatic fibrosis: a manifestation of the liver disease evolution in patients with Ataxia-telangiectasia
Background: Ataxia-telangiectasia (A-T) is a DNA repair disorder characterized by changes in several organs and systems. Advances in clinical protocols have resulted in increased survival of A-T patients, however disease progression is evident, mainly through metabolic and liver changes. Objective: To identify the frequency of significant hepatic fibrosis in A-T patients and to verify the association with metabolic alterations and degree of ataxia. Methods: This is a cross-sectional study that included 25 A-T patients aged 5 to 31 years. Anthropometric data, liver, inflammatory, lipid metabolism and glucose biomarkers (oral glucose tolerance test with insulin curve—OGTT) were collected. The Cooperative Ataxia Rating Scale was applied to assess the degree of ataxia. The following were calculated: Homeostasis Model Assessment—Insulin Resistance, Homeostasis Model Assessment—Adiponectin (HOMA-AD), Matsuda index, aspartate aminotransferase (AST): platelet ratio index, nonalcoholic fatty liver disease fibrosis score and BARD score. Liver ultrasonography and transient liver elastography by FibroScan® were performed. Results: Significant hepatic fibrosis was observed in 5/25 (20%). Patients in the group with significant hepatic fibrosis were older (p < 0.001), had lower platelet count values (p = 0.027), serum albumin (p = 0.019), HDL-c (p = 0.013) and Matsuda index (p = 0.044); and high values of LDL-c (p = 0.049), AST (p = 0.001), alanine aminotransferase (p = 0.002), gamma-glutamyl transferase (p = 0.001), ferritin (p = 0.001), 120-min glycemia by OGTT (p = 0.049), HOMA-AD (p = 0.016) and degree of ataxia (p = 0.009). Conclusions: A non-invasive diagnosis of significant hepatic fibrosis was observed in 20% of A-T patients associated with changes in liver enzymes, ferritin, increased HOMA-AD, and the severity of ataxia in comparison with patients without hepatic fibrosis.
- Open Access
- 1 March 2022
- Published by FapUNIFESP (SciELO) in Arquivos de Gastroenterologia
- Vol. 59 (1) , 65-70
HEPATIC ALTERATIONS IN KIDNEY TRANSPLANT RECIPIENTS FROM THE LARGEST KIDNEY TRANSPLANT CENTER IN BRAZIL
Background Kidney transplant is the treatment of choice for patients with end-stage renal disease and is associated with lower mortality when compared to dialysis methods. Brazil is the country with the second largest number of kidney transplants in the world and among these patients it has been observed that liver abnormalities are common. The frequency of liver abnormalities ranges from 20-50% post-transplantation, and have an important impact on the survival and quality of life of these patients. There are scarce data about the frequency, causes and characteristics of these alterations. Objective To determine the prevalence of the different causes of hepatic abnormalities in kidney transplant recipients, to associate the characteristics of these abnormalities with demographic, epidemiological and clinical variables, to compare the characteristics of hepatic alterations between different etiologies, and to evaluate possible changes in diagnosis over two different periods of time. Methods Descriptive, cross-sectional observational, epidemiological study was conducted at the outpatient “Hepato-Rim”clinic of Hospital São Paulo (EPM/UNIFESP), a center providing specialized care for patients with hepatic abnormalities and underlying kidney diseases. Results Five-hundred eighty-one transplant patients were evaluated. The most prevalent etiologies of liver abnormalities were hepatitis C and B, iron overload, nonalcoholic fatty liver disease (NAFLD), and drug-induced liver injury (DILI). The most common cause — hepatitis C — was analyzed in greater detail. Compared to the other causes, this infection was more frequent in older patients, female patients, and patients with a longer time since transplantation and hemodialysis. Analysis of the two periods showed that patients of period 1 (P1 — 1993 to 2005) were older and were more frequently referred because of positive serology; referral due to aminotransferases abnormalities predominated during period 2 (P2 — 2006 to 2018). The predominant diagnoses were hepatitis C and B during P1 and NAFLD and DILI during P2. Conclusion Assessment of the main hepatic alterations in kidney transplant recipients is important because it permits better management of these patients in terms of diagnostic investigation and treatment and contributes to the prevention of complications in this special population.
- 1 March 2022
- Published by FapUNIFESP (SciELO) in Arquivos de Gastroenterologia
- Vol. 59 (1) , 65-70
Open AccessHEPATIC ALTERATIONS IN KIDNEY TRANSPLANT RECIPIENTS FROM THE LARGEST KIDNEY TRANSPLANT CENTER IN BRAZIL
Background Kidney transplant is the treatment of choice for patients with end-stage renal disease and is associated with lower mortality when compared to dialysis methods. Brazil is the country with the second largest number of kidney transplants in the world and among these patients it has been observed that liver abnormalities are common. The frequency of liver abnormalities ranges from 20-50% post-transplantation, and have an important impact on the survival and quality of life of these patients. There are scarce data about the frequency, causes and characteristics of these alterations. Objective To determine the prevalence of the different causes of hepatic abnormalities in kidney transplant recipients, to associate the characteristics of these abnormalities with demographic, epidemiological and clinical variables, to compare the characteristics of hepatic alterations between different etiologies, and to evaluate possible changes in diagnosis over two different periods of time. Methods Descriptive, cross-sectional observational, epidemiological study was conducted at the outpatient “Hepato-Rim”clinic of Hospital São Paulo (EPM/UNIFESP), a center providing specialized care for patients with hepatic abnormalities and underlying kidney diseases. Results Five-hundred eighty-one transplant patients were evaluated. The most prevalent etiologies of liver abnormalities were hepatitis C and B, iron overload, nonalcoholic fatty liver disease (NAFLD), and drug-induced liver injury (DILI). The most common cause — hepatitis C — was analyzed in greater detail. Compared to the other causes, this infection was more frequent in older patients, female patients, and patients with a longer time since transplantation and hemodialysis. Analysis of the two periods showed that patients of period 1 (P1 — 1993 to 2005) were older and were more frequently referred because of positive serology; referral due to aminotransferases abnormalities predominated during period 2 (P2 — 2006 to 2018). The predominant diagnoses were hepatitis C and B during P1 and NAFLD and DILI during P2. Conclusion Assessment of the main hepatic alterations in kidney transplant recipients is important because it permits better management of these patients in terms of diagnostic investigation and treatment and contributes to the prevention of complications in this special population.
- Open Access
- 18 June 2021
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 25 (3) , 101589
Assessment of liver disease by non-invasive methods in perinatally infected Brazilian adolescents and young adults living with Human Immunodeficiency Virus (HIV)
- 18 June 2021
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 25 (3) , 101589
Open AccessAssessment of liver disease by non-invasive methods in perinatally infected Brazilian adolescents and young adults living with Human Immunodeficiency Virus (HIV)
- Open Access
- 1 February 2020
- Published by FapUNIFESP (SciELO) in Arquivos de Gastroenterologia
- Vol. 57 (1) , 45-49
HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR
BACKGROUND: Direct-acting antivirals have revolutionized hepatitis C treatment, also for patients with chronic kidney disease (CKD), but some controversy exists regarding the use of sofosbuvir (SOF) in patients with glomerular filtration rate (GFR) <30 mL/min. OBJECTIVE: To evaluate the efficacy and safety of these regimens for hepatitis C treatment of patients with CKD and after renal transplantation, as well as the impact of SOF on renal function in non-dialysis patients. METHODS: All patients with hepatitis C and CKD or renal transplant treated with direct-acting antivirals at a referral center in Brazil between January 2016 and August 2017 were included. Efficacy was evaluated based on viral load (HCV RNA) and a sustained virological response (SVR) consisting of undetectable RNA 12 and/or 24 weeks after the end of treatment (SVR12 and SVR24) was defined as cure. Safety was determined by adverse events and ribavirin, when combined, was administered in escalating doses to all patients with GFR <60 mL/min. The impact of SOF on renal function was determined by the measurement of baseline creatinine during and after the end of treatment and its increase was evaluated using the Acute Kidney Injury Network (AKIN) classification. RESULTS: A total of 241 patients (52.7% females) with a mean age of 60.72±10.47 years were included. The combination of SOF+daclatasvir was the predominant regimen in 75.6% of cases and anemia was present in 28% of patients who used ribavirin (P=0.04). The SVR12 and SVR24 rates were 99.3% and 97.1%, respectively. The treatment was well tolerated and there were no major clinically relevant adverse events, with the most prevalent being asthenia (57.7%), itching (41.1%), headache (40.7%), and irritability (40.2%). Among conservatively treated and renal transplant patients, oscillations of creatinine levels (AKIN I) were observed in 12.5% of cases during treatment and persisted in only 8.5% after the end of treatment. Of these, 2.0% had an initial GFR <30 mL/min and this percentage decreased to 1.1% after SOF use. Only 0.5% and 1.6% of the patients progressed to AKIN II and AKIN III elevation, respectively. CONCLUSION: The direct-acting antivirals were safe and efficacious in CKD patients treated with SOF-containing regimens, with the observation of high SVR rates, good tolerability and few severe adverse events. The combination with ribavirin increased the risk of anemia and the administration of escalating doses seems to be useful in patients with GFR <60 mL/min. In patients with GFR <30 mL/min, SOF had no significant renal impact, with serum creatinine returning to levels close to baseline after treatment.
- 1 February 2020
- Published by FapUNIFESP (SciELO) in Arquivos de Gastroenterologia
- Vol. 57 (1) , 45-49
Open AccessHEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR
BACKGROUND: Direct-acting antivirals have revolutionized hepatitis C treatment, also for patients with chronic kidney disease (CKD), but some controversy exists regarding the use of sofosbuvir (SOF) in patients with glomerular filtration rate (GFR) <30 mL/min. OBJECTIVE: To evaluate the efficacy and safety of these regimens for hepatitis C treatment of patients with CKD and after renal transplantation, as well as the impact of SOF on renal function in non-dialysis patients. METHODS: All patients with hepatitis C and CKD or renal transplant treated with direct-acting antivirals at a referral center in Brazil between January 2016 and August 2017 were included. Efficacy was evaluated based on viral load (HCV RNA) and a sustained virological response (SVR) consisting of undetectable RNA 12 and/or 24 weeks after the end of treatment (SVR12 and SVR24) was defined as cure. Safety was determined by adverse events and ribavirin, when combined, was administered in escalating doses to all patients with GFR <60 mL/min. The impact of SOF on renal function was determined by the measurement of baseline creatinine during and after the end of treatment and its increase was evaluated using the Acute Kidney Injury Network (AKIN) classification. RESULTS: A total of 241 patients (52.7% females) with a mean age of 60.72±10.47 years were included. The combination of SOF+daclatasvir was the predominant regimen in 75.6% of cases and anemia was present in 28% of patients who used ribavirin (P=0.04). The SVR12 and SVR24 rates were 99.3% and 97.1%, respectively. The treatment was well tolerated and there were no major clinically relevant adverse events, with the most prevalent being asthenia (57.7%), itching (41.1%), headache (40.7%), and irritability (40.2%). Among conservatively treated and renal transplant patients, oscillations of creatinine levels (AKIN I) were observed in 12.5% of cases during treatment and persisted in only 8.5% after the end of treatment. Of these, 2.0% had an initial GFR <30 mL/min and this percentage decreased to 1.1% after SOF use. Only 0.5% and 1.6% of the patients progressed to AKIN II and AKIN III elevation, respectively. CONCLUSION: The direct-acting antivirals were safe and efficacious in CKD patients treated with SOF-containing regimens, with the observation of high SVR rates, good tolerability and few severe adverse events. The combination with ribavirin increased the risk of anemia and the administration of escalating doses seems to be useful in patients with GFR <60 mL/min. In patients with GFR <30 mL/min, SOF had no significant renal impact, with serum creatinine returning to levels close to baseline after treatment.
- Open Access
- 1 June 2019
- Published by FapUNIFESP (SciELO) in Arquivos de Gastroenterologia
- Vol. 56 (2) , 232-241
UPDATE OF THE BRAZILIAN SOCIETY OF HEPATOLOGY RECOMMENDATIONS FOR DIAGNOSIS AND MANAGEMENT OF AUTOIMMUNE DISEASES OF THE LIVER
New data concerning the management of autoimmune liver diseases have emerged since the last single-topic meeting sponsored by the Brazilian Society of Hepatology to draw recommendations about the diagnosis and treatment of autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), overlap syndromes of AIH, PBC and PSC and specific complications and topics concerning AIH and cholestatic liver diseases. This manuscript updates those previous recommendations according to the best evidence available in the literature up to now. The same panel of experts that took part in the first consensus document reviewed all recommendations, which were subsequently scrutinized by all members of the Brazilian Society of Hepatology using a web-based approach. The new recommendations are presented herein.
- 1 June 2019
- Published by FapUNIFESP (SciELO) in Arquivos de Gastroenterologia
- Vol. 56 (2) , 232-241
Open AccessUPDATE OF THE BRAZILIAN SOCIETY OF HEPATOLOGY RECOMMENDATIONS FOR DIAGNOSIS AND MANAGEMENT OF AUTOIMMUNE DISEASES OF THE LIVER
New data concerning the management of autoimmune liver diseases have emerged since the last single-topic meeting sponsored by the Brazilian Society of Hepatology to draw recommendations about the diagnosis and treatment of autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), overlap syndromes of AIH, PBC and PSC and specific complications and topics concerning AIH and cholestatic liver diseases. This manuscript updates those previous recommendations according to the best evidence available in the literature up to now. The same panel of experts that took part in the first consensus document reviewed all recommendations, which were subsequently scrutinized by all members of the Brazilian Society of Hepatology using a web-based approach. The new recommendations are presented herein.
- Open Access
- 1 December 2018
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 12, 65-66
Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]
Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum] Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]Tavares RCF, Feldner AC, Pinho JR, et al. Infect Drug Resist. 2018;11:1993–2000.Page 1999, reference 40 was listed incorrectly. “Alves da Silva R. Molecular characterization of hepatitis C virus in end-stage renal disease patients under hemodialysis. Journal of Medical Virology 90. 2018;3:537–544.” should read “Alves da Silva R, Todão JS, Kamitani FL, et al. Molecular characterization of hepatitis C virus in end-stage renal disease patients under hemodialysis. Journal of Medical Virology 90. 2018;3:537–544.”Read the original article
- 1 December 2018
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 12, 65-66
Open AccessPrevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]
Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum] Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]Tavares RCF, Feldner AC, Pinho JR, et al. Infect Drug Resist. 2018;11:1993–2000.Page 1999, reference 40 was listed incorrectly. “Alves da Silva R. Molecular characterization of hepatitis C virus in end-stage renal disease patients under hemodialysis. Journal of Medical Virology 90. 2018;3:537–544.” should read “Alves da Silva R, Todão JS, Kamitani FL, et al. Molecular characterization of hepatitis C virus in end-stage renal disease patients under hemodialysis. Journal of Medical Virology 90. 2018;3:537–544.”Read the original article